Investors Sue Fertility Treatment Co. Following FDA Letter

Law360, New York (September 16, 2013, 6:00 PM EDT) -- OvaScience Inc. and its top brass were hit with a putative shareholder class action Monday following a company announcement that it was suspending trials of its flagship fertility treatment because of drug classification concerns by the U.S. Food and Drug Administration.

Cambridge, Mass.-based OvaScience was sued in Massachusetts federal court by Meriam Ratner, an investor who claimed the life sciences company misrepresented that its fertility treatment Augment would not need FDA approval to be tested or marketed. The FDA announced on Sept. 10 that the treatment...
To view the full article, register now.




Case Information

Case Title

Ratner v. OvaScience, Inc. et al

Case Number




Nature of Suit



William G. Young

Date Filed

September 16, 2013

Law Firms

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.